Genentech uses an iterative AI model where an algorithm predicts an experiment, scientists run it in a wet lab, and the results are fed back to improve the model. This human-in-the-loop system has dramatically increased R&D productivity, cutting molecule design time from a typical 36 months down to just 10.

Instead of building from scratch, ProPhet leverages existing transformer models to create unique mathematical 'languages' for proteins and molecules. Their core innovation is an additional model that translates between them, creating a unified space to predict interactions at scale.

A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

AI isn't just for designing RNA sequences. Its real value is in creating predictive models of complex cellular functions. This allows scientists to determine the precise set of instructions (RNAs) needed to make a cell perform a complex series of tasks, like targeting a brain tumor.

Earli combines wet lab experiments with AI in a continuous feedback loop. They test massive libraries of synthetic DNA promoter sequences, feed the performance results into a Large Language Model (LLM), which then designs new, potentially more effective sequences. This iterative process rapidly optimizes their cancer-specific genetic switches.

Reversing the age of a mouse retina surprisingly caused the spontaneous clearance of protein buildups associated with macular degeneration. This suggests that restoring a cell's youthful epigenetic state also reactivates its innate ability to clean and repair itself, a promising sign for treating diseases like Alzheimer's.

For patients with ultra-rare diseases, traditional drug development is too slow. AI platforms like Therna's can design a custom RNA molecule in days and complete the lab-testing cycle in under three months, compressing a multi-year process and making previously impossible treatments viable.

Generate Biomedicines' AI learns the fundamental rules of protein structure and function, much like a language's grammar. This allows it to design entirely new proteins by generating novel "sentences" (sequences) that are biologically coherent and functional, rather than just mimicking existing ones found in nature.

A major biotech revolution is underway as AI now enables effective 'in silico' (simulated) experiments. This shift from physical "wet labs" to cheap, infinitely scalable simulations drastically cuts time and cost for drug discovery, making audacious goals like curing cancer scientifically plausible.